Skip to content

Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Primary Angle Closure Glaucoma

Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Chinese Primary Angle Closure Glaucoma

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02964676
Enrollment
246
Registered
2016-11-16
Start date
2017-01-31
Completion date
2019-12-31
Last updated
2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Angle-Closure

Brief summary

To evaluate the clinical efficacy (intraocular pressure reduction , success rate, the number of antiglaucoma medication) and safety of ab interno trabeculectomy (AIT) with Trabectome in Chinese PACG .

Detailed description

A randomized, single blind, positive parallel control study method was used.This prospective case series will recruit 246 Chinese POAG, 123 cases in the experimental group will receive AIT treatment and 123 cases in the control group will receive trabeculectomy(Trab) surgery.Measurements of intraocular pressure(IOP) , visual acuity, refraction, slit lamp examination of the anterior segment and fundus, optical coherence tomography(OCT) to detect retinal nerve fiber layer thickness, macular thickness, visual field, gonioscopy and ultrasonic biological microscopy (UBM) will be recorded.They will be followed up for 12 months. The main outcome is success rate of IOP reduction and the other outcome are the number of antiglaucoma medication and complications .

Interventions

PROCEDUREab interno trabeculectomy with Trabectome

123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly

PROCEDUREtrabeculectomy

123 PACG will be recruited to receive trabeculectomy to reduce IOP

Sponsors

Shanghai Eye Disease Prevention and Treatment Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primary Angle Closure Glaucoma (PACG) with visible trabecular meshwork from 90︒ to 180︒ on gonioscopy and IOP couldn't be controlled ≤21mmHg with pilocarpine eye drop only. * willing to accept the antiglaucoma surgery * volunteer to participate in this study and be able to follow up on time * previous antiglaucoma filtering surgery or laser surgery(LPI, SLT) and previous cataract surgery were not ruled out *

Exclusion criteria

* visual acuity lower than HM or central tubular visual field * corneal edema or large pterygium affecting the observation of anterior angle * the demarcation of the scleral process and trabecular meshwork is not clear on gonioscopy * new vessels on the iris surface or in the anterior angle chamber * the eye received surgery is the only eye with visual function, that is the contralateral eye is blind * requiring long-term use of anticoagulant drugs for systemic reasons * abnormal coagulation function * with specific clear scar physique * cannot participate in follow-up

Design outcomes

Primary

MeasureTime frameDescription
success rate of IOP reduction12 monthsIOP ≤21mmHg and IOP reduction rate ≥20% with or without antiglaucoma medications and without additional glaucoma surgery

Secondary

MeasureTime frameDescription
number of antiglaucoma medication12 monthsnumbers of antiglaucoma medication will be recorded before surgery and 12 months follow up.
complication rate12 monthsall the complications related to the surgery will be evaluated and recorded.
24-hour IOP fluctuations12 months24-hour IOP fluctuations curve will be recorded before treatment and 12 months follow up.

Contacts

Primary ContactLING GE, M.d.
geling99@sina.com+86-21-62717733
Backup ContactXIAOLING FANG, M.d.
fangxl0617@hotmail.com+86-21-62717733

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026